May 19, 2008 Kythera Biopharmaceuticals Announces $40M Financing — Series C Round Led by JAFCO —
April 15, 2008 Kythera Biopharmaceuticals Announces Second Phase II Clinical Trial with Adipolytic Agent for Reduction of Submental Fat
February 14, 2008 Joseph L. Turner Appointed to Kythera Board of Directors
December 20, 2007 Kythera Biopharmaceuticals Announces Discontinuation of Actinic Keratosis Clinical Program
November 29, 2007 Kythera Biopharmaceuticals Appoints Amgen Veteran as Chief Financial Officer
November 14, 2007 Kythera Biopharmaceuticals Appoints Industry Veteran as Vice President, Regulatory Affairs
August 28, 2007 Kythera Biopharmaceuticals Initiates Phase II Study of its Adipolytic Agent for Reduction of Submental Fat
April 24, 2007 Kythera Biopharmaceuticals Appoints New Chief Medical Officer
April 24, 2007 Kythera Biopharmaceuticals Appoints Vice President, Product Development and Operations
January 8, 2007 Kythera Biopharmaceuticals Announces Initiation of Phase I/II Clinical Trial for Lead Product Candidate
January 8, 2007 Kythera Biopharmaceuticals Signs Agreement For Access To Worldwide Rights For Topical Agent For The Treatment Of Actinic Keratosis
November 15, 2006 Kythera Biopharmaceuticals Names Keith Klein As General Counsel
July 24, 2006 Kythera Raises $30 Million in Series B Financing; Three new directors named to board
